Amwill Healthcare IPO Closed
Already have an account? Apply now
Schedule of Amwill Healthcare
| Issue open date | 05 Feb 2025 |
| Issue close date | 07 Feb 2025 |
| UPI mandate deadline | 07 Feb 2025 (5 PM) |
| Allotment finalization | 10 Feb 2025 |
| Refund initiation | 11 Feb 2025 |
| Share credit | 11 Feb 2025 |
| Listing date | 12 Feb 2025 |
| Mandate end date | 20 Feb 2025 |
| Lock-in end date for anchor investors (50%) | 12 Mar 2025 |
| Lock-in end date for anchor investors (remaining) | 11 May 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Amwill Healthcare
Amwill Healthcare, a derma-cosmetic developer, focuses on innovative dermatological solutions by outsourcing manufacturing and distribution to enhance product formulation. Led by founder Anand Gandhi, the company specializes in both generic and specific skin treatments, with a significant presence in Karnataka, Andhra Pradesh, and Telangana. Amwill leverages expert insights from dermatologists to ensure high-quality, compliant products through partnerships with certified contract manufacturers. The company strategically uses its affiliate, Amderma Healthcare LLP, for streamlined storage and distribution, preparing for expansion into new regional markets.
Financials of Amwill Healthcare
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹59.98 crores |
| Fresh Issue | ₹48.88 crore |
| Offer for Sale | ₹11.10 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Working Capital | 25 (51.2%) |
| Marketing and brand-building activities | 5 (10.2%) |
| General corporate purposes | 18.88 (38.6%) |
Strengths
- Specializes in derma-cosmetic solutions targeting a growing skincare market.
- Strong ties with dermatologists enhance product innovation and effectiveness.
- Outsourced manufacturing focuses resources on product development.
- Solid market presence in Karnataka, Andhra Pradesh, and Telangana supports expansion.
Risks
- No historical market for shares may lead to price volatility post-IPO.
- Dependency on third-party manufacturers risks quality and supply issues.
- Faces intense competition in a rapidly evolving skincare industry.
- Regulatory compliance risks could impact operations and finances.
Allotment Status for Amwill Healthcare
To check your allotment status – click here.
Subscription Figures for Amwill Healthcare
Subscription numbers as of 5:00 PM on 7 Feb 2025:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 10.26 | 80.01 | 7.80x |
| HNI (₹2L+) | 23.24 | 118.92 | 5.12x |
| Retail (upto ₹2L) | 20.53 | 97.83 | 4.77x |
| Total | 54.03 | 296.77 | 5.49x |